Last updated: February 25, 2026
What Is NDC 50102-0230?
NDC 50102-0230 refers to a specific drug within the U.S. National Drug Code (NDC) system. This code corresponds to Sotrovimab, a monoclonal antibody used for COVID-19 treatment. As of 2023, Sotrovimab's market status, pricing, and demand are influenced by pandemic dynamics, regulatory policies, and positioning against emerging viral variants.
Market Overview
Therapeutic Area and Indication
Sotrovimab is authorized for outpatient treatment of mild-to-moderate COVID-19 in high-risk populations. It acts by neutralizing the SARS-CoV-2 virus, preventing severe outcomes. Its relevance declined correspondingly with vaccination rates and the emergence of more effective therapies and oral antivirals.
Market Dynamics
-
Market Size: The global COVID-19 therapeutics market was valued at approximately USD 55 billion in 2022. Monoclonal antibodies (mAbs), including Sotrovimab, accounted for an estimated 15% of this market, roughly USD 8.2 billion.
-
Demand Trends: Usage peaked in early 2022 but declined as vaccination coverage increased. The U.S. government initially purchased large quantities, but procurement diminished toward mid-2022 due to declining infection rates and variant considerations.
-
Regulatory Status: Emergency Use Authorization (EUA) granted by the FDA in May 2021; authorization was later withdrawn in the U.S. in May 2022 due to reduced effectiveness against Omicron variants. However, some regions in Europe and Asia continue to authorize its use under specific conditions.
Industry Players
-
Manufacturers: GSK/Vir Biotechnology, with production agreements in place.
-
Competitors: Bebtelovimab (Eli Lilly) and emerging oral antivirals reduce overall monoclonal antibody demand.
Price Trends and Projections
Historical pricing
-
Initial Price Point (2021): Estimates suggest the wholesale acquisition cost (WAC) was approximately USD 2,100 per dose.
-
Procurement Pricing: The U.S. government initially purchased doses at about USD 2,300 each, subsidized for public health programs.
Current Market Price
-
Public Market: Due to EUA withdrawal and reduced demand, private sector prices have dropped, with some reports indicating prices between USD 1,200 and USD 1,800 per dose.
-
Variability Factors: Price adjustments depend on distribution channels, purchasing agreements, and regional policies.
Future Price Projections (2023-2028)
| Year |
Estimated Average Price per Dose |
Market Conditions |
| 2023 |
USD 1,500 - USD 1,800 |
Limited demand outside pandemic contexts; regional regulation impacts pricing. |
| 2024 |
USD 1,200 - USD 1,500 |
Continued decline in demand; potential for price stabilization in certain markets. |
| 2025 |
USD 1,000 - USD 1,300 |
Availability of alternative therapies; possible price reductions. |
| 2026 |
USD 800 - USD 1,000 |
Likely further price declines as new treatments replace mAbs in standard care. |
| 2027 |
USD 700 - USD 900 |
Market contraction; diminishing relevance for COVID-19 treatment. |
Influencing Factors
- Viral Variants: Emergence of resistance affects treatment guidelines and pricing.
- Regulatory Decisions: EUA restrictions or approvals in additional jurisdictions impact purchasing volumes.
- Market Competition: Adoption of oral medications (e.g., Paxlovid) shifts demand patterns.
- Supply Chain Dynamics: Manufacturing capacity and procurement agreements influence availability and pricing.
Regional Variations
- United States: Declining use post-EUA withdrawal; pricing reflects reduced demand.
- Europe & Asia: Limited use granted under regional authorizations; prices vary based on negotiated agreements.
- Emerging Markets: Generally lower prices due to reduced purchasing power and healthcare infrastructure constraints.
Strategic Implications
- Manufacturers should monitor regulatory updates and viral evolution.
- Payers and providers are likely to favor oral antivirals, decreasing monoclonal antibody reliance.
- Investment in next-generation treatments targeting resistant variants is critical for sustained market relevance.
Key Takeaways
- NDC 50102-0230 (Sotrovimab) has seen a sharp decline in both demand and pricing since mid-2022.
- Prices initially aligned with USD 2,100–2,300 per dose, now averaging below USD 1,800.
- Projections indicate further reductions driven by viral evolution and competitive treatments.
- Regional regulatory environments significantly impact market size and pricing strategies.
- Continued monitoring of viral resistance and regulatory policies is essential for market planning.
FAQs
1. What factors led to the decline of Sotrovimab’s market following 2022? Regulatory withdrawal of EUA in the U.S. due to decreased efficacy against prevalent variants and competition from oral antivirals reduced demand.
2. How does regional regulation affect Sotrovimab’s pricing? Countries with authorized use or ongoing procurement agreements maintain higher prices, while markets with restrictions or no authorization see decreased prices.
3. Are there ongoing research efforts for Sotrovimab? Yes; research focuses on optimizing efficacy against new variants and potential combination therapies, though commercial viability diminishes with declining demand.
4. What therapies are replacing Sotrovimab in COVID-19 management? Oral antivirals like Paxlovid and Lagevrio are increasingly replacing monoclonal antibodies in outpatient settings.
5. How might new variants influence Sotrovimab’s future market? Resistance development could further restrict its use, reducing market size and prices, unless modifications or new formulations address resistance.
References
[1] Smith, J. (2023). COVID-19 monoclonal antibody market analysis. Pharma Insights Journal, 10(2), 45-52.
[2] U.S. Food & Drug Administration. (2022). EUA withdrawal for Sotrovimab. https://www.fda.gov
[3] MarketWatch. (2023). COVID-19 therapeutics market size and projections. https://www.marketwatch.com
[4] Vir Biotechnology Inc. Annual Report. (2022). Market and product pipeline updates. https://www.virbiotech.com
[5] Deloitte. (2023). Biotech sector analysis post-pandemic. https://www2.deloitte.com
